Stock Events

Stock Events

Spyre Therapeutics 

€90.50
0
+€4.00+4.62%Friday 16:30

Statistics

Day High
86
Day Low
86
52W High
90.5
52W Low
71.5
Volume
-
Avg. Volume
-
Mkt Cap
8.46B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 3Expected
Q2 2026
Q3 2026
-0.84
-0.66
-0.49
-0.31
Expected EPS
-0.733465732
Actual EPS
-0.83848

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-135.36MNet Income

Analyst Ratings

$91.81Average Price Target
The highest estimate is ⁦102.44⁩.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
89%
Hold
11%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3920.XETRA. It's not an investment recommendation.
Apple
9
AAPL
NVIDIA
9
NVDA
Intel
9
INTC
Micron Technology
8
MU

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other serious diseases, directly competing in some of the same therapeutic areas as Spyre Therapeutics.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas such as viral diseases, inflammatory and fibrotic diseases, which overlaps with Spyre Therapeutics' focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is known for its innovations in biotechnology, including treatments for rare diseases, which competes with Spyre Therapeutics' efforts in novel therapeutics.
AMGEN
AMGN
Mkt Cap251.94B
Amgen develops biologic therapies, focusing on oncology and cardiovascular diseases, competing with Spyre Therapeutics in the biopharmaceutical sector.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurological diseases and innovative therapies, which might overlap with Spyre Therapeutics' research and development in similar therapeutic areas.
Incyte
INCY
Mkt Cap24.54B
Incyte Corporation works on small molecule drugs for oncology and inflammation, competing with Spyre Therapeutics in these crucial healthcare segments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap22.1B
Alnylam Pharmaceuticals develops RNAi therapeutics, a novel approach that could be in direct competition with Spyre Therapeutics' innovative drug development strategies.
Exelixis
EXEL
Mkt Cap16.93B
Exelixis is involved in the discovery, development, and commercialization of new cancer treatments, potentially competing with Spyre Therapeutics in the oncology sector.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and rare genetic diseases treatments, areas that might intersect with Spyre Therapeutics' interests.

About

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Show More
CEO
Cameron Turtle
Employees
112
Country
United States
ISIN
US00773J2024
WKN
000A3D4LY

Listings

STU
DE
3920.STU
XNAS
US
SYRE
F
DE
3920.F
MU
DE
3920.MU

0 Comments

Share your thoughts

FAQs

What is Spyre Therapeutics stock price today?▼
The current price of 3920.XETRA is €90.50 EUR — it has increased by +4.62% in the past 24 hours. Watch Spyre Therapeutics stock price performance more closely on the chart.
What is Spyre Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Spyre Therapeutics stocks are traded under the ticker 3920.XETRA.
What is Spyre Therapeutics market cap?▼
Today Spyre Therapeutics has the market capitalization of 8.46B
When is the next Spyre Therapeutics earnings date?▼
Spyre Therapeutics is going to release the next earnings report on March 4, 2027.
What were Spyre Therapeutics earnings last quarter?▼
3920.XETRA earnings for the last quarter are -0.84 EUR per share, whereas the estimation was -0.73 EUR resulting in a -14.32% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Spyre Therapeutics revenue for the last year?▼
Spyre Therapeutics revenue for the last year amounts to 0 EUR.
What is Spyre Therapeutics net income for the last year?▼
3920.XETRA net income for the last year is -135.36M EUR.
How many employees does Spyre Therapeutics have?▼
As of November 8, 2026, the company has 112 employees.
In which sector is Spyre Therapeutics located?▼
Spyre Therapeutics operates in the Health & Wellness sector.
When did Spyre Therapeutics complete a stock split?▼
The last stock split for Spyre Therapeutics was on September 8, 2023 with a ratio of 1:25.
Where is Spyre Therapeutics headquartered?▼
Spyre Therapeutics is headquartered in WALTHAM, United States.